A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA)

CompletedOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

February 22, 2022

Primary Completion Date

March 12, 2024

Study Completion Date

March 12, 2024

Conditions
Inflammatory Bowel DiseasesCrohns DiseaseColitis, Ulcerative
Trial Locations (8)

1000

Univerzitetni klinicni center Ljubljana (University medical Centre Ljubljana), Ljubljana

2000

Univerzitetni klinicni center Maribor (University medical centre Maribor), Maribor

3000

Splosna bolnisnica Celje (General hospital Celje), Celje

10000

Klinicki bolnicki centar Sestre milosrdnice (University medical centre Sestre milosrdnice), Zagreb

Klinicki bolnicki centar Zagreb (University medical centre Zagreb), Zagreb

21000

Klinicki bolnicki centar Split (University medical centre Split), Split

31000

Klinicki bolnicki centar Osijek (University medical centre Osijek), Osijek

51000

Klinicki bolnicki centar Rijeka (University medical centre Rijeka), Rijeka

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT04885920 - A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA) | Biotech Hunter | Biotech Hunter